Spyre Therapeutics
SYRE
92 hedge funds and large institutions have $319M invested in Spyre Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 12 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
16% more capital invested
Capital invested by funds: $275M → $319M (+$44.2M)
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
0.02% less ownership
Funds ownership: 3.48% → 3.46% (-0.02%)
2% less funds holding
Funds holding: 94 → 92 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $551K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.2M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$11.5M |
| 3 |
Millennium Management
New York
|
+$3.35M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$1.9M |
| 5 |
BlackRock
New York
|
+$930K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$9.53M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$8.04M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.66M |
| 4 |
Renaissance Technologies
New York
|
-$2.47M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.04M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Osaic Holdings
Scottsdale,
Arizona
| – | -$6K | -31 | Closed |
|
|
PCM
102
Prelude Capital Management
New York
| – | -$3K | -16 | Closed |
|
103
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3K | -15 | Closed |
|
104
Simplex Trading
Chicago,
Illinois
| – | +$415 | +2 | +67% |
|
SYRE Hedge Fund Activity: Q4 2020 in Review
92 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2020, worth a combined $319M — up 16% from $275M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SYRE and 10 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 33 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $24.2M. The largest seller was Nantahala Capital Management, cutting an estimated $9.53M.
- 92 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2020, down from 94 in Q3 2020.
- Funds reported $319M of Spyre Therapeutics stock for Q4 2020, up 16% quarter-over-quarter.
- 10 funds opened new Spyre Therapeutics positions in Q4 2020 and 12 closed out, a net change of -2 holders.
- The largest Spyre Therapeutics buyer in Q4 2020 was Point72 Asset Management, an estimated $24.2M added.
- The largest Spyre Therapeutics seller in Q4 2020 was Nantahala Capital Management, an estimated $9.53M sold.
Based on aggregated 13F filings for Q4 2020.